MDL 101146
Modify Date: 2024-01-05 15:51:40
MDL 101146 structure
|
Common Name | MDL 101146 | ||
|---|---|---|---|---|
| CAS Number | 149859-17-6 | Molecular Weight | 632.61900 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C29H37F5N4O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MDL 101146MDL 101146 is an orally active neutrophil elastase inhibitor. MDL 101146 inhibits neutrophil elastase for human with a Ki value of 25 nM. MDL 101146 can be used for the research of arthritis[1][2]. |
| Name | mdl 101,146 |
|---|---|
| Synonym | More Synonyms |
| Description | MDL 101146 is an orally active neutrophil elastase inhibitor. MDL 101146 inhibits neutrophil elastase for human with a Ki value of 25 nM. MDL 101146 can be used for the research of arthritis[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Ki for neutrophil elastase: 25 nM (human); 18 nM (rat)[1][2] |
| In Vitro | MDL 101,146 inhibits human neutrophil elastase with a Ki value of 25 nM[1]. MDL 101,146 inhibits rat neutrophil elastase activity in a dose-related manner with a Ki value of 18 nM[2]. |
| In Vivo | MDL 101146 (oral, 200 mg/kg/day) significantly inhibits swelling and joint destruction in collagen-induced arthritis but not in adjuvant arthritis[2]. Animal Model: Rats[2] Dosage: 200 mg/kg Administration: Oral, 200 mg/kg/day Result: Inhibited the severity of collagen-induced arthritis. Had a bone and cartilage sparing effect in the tibio-tarsal joint of animals with collagen-induced arthritis. |
| Molecular Formula | C29H37F5N4O6 |
|---|---|
| Molecular Weight | 632.61900 |
| Exact Mass | 632.26300 |
| PSA | 125.12000 |
| LogP | 3.46950 |
| N-[4-(4-morpholinylcarbonyl)benzoyl]-L-valyl-N-[3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]-L-prolinamide |
| (S)-1-{(S)-3-Methyl-2-[4-(morpholine-4-carbonyl)-benzoylamino]-butyryl}-pyrrolidine-2-carboxylic acid (3,3,4,4,4-pentafluoro-1-isopropyl-2-oxo-butyl)-amide |
| [4-(4-morpholinylcarbonyl)benzoyl]Val-Pro-L,D-Val pentafluoroethylketone |